Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerRasburicase (Elitek): a novel agent for tumor lysis syndrome.The tumor lysis syndromeRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutRecognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesA focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologistA review in the treatment of oncologic emergencies.Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase.What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceGene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatmentTreatment of Burkitt lymphoma in adults.Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapyRasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group ReportOne for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects.Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Burkitt lymphoma in adults.Tumor lysis syndrome: a systematic review of case series and case reports.Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Hemolytic anemia following rasburicase administration: a review of published reports.Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.Tumor lysis syndrome in the emergency department: challenges and solutions.Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia.Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.Childhood acute lymphoblastic leukemia.Serum uric acid and acute kidney injury: A mini review.Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count.Urolithiasis in pediatric patients with acute lymphoblastic leukemia.Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
P2860
Q24194387-F4DFD82C-3096-41CA-949E-EEF1D696BBD8Q24531989-8102D1D4-D171-4497-92F5-0ED7175E4DCEQ24605151-F6DC35E0-52A7-4502-85B2-19EB56689141Q24673444-77A35C14-D967-479B-B0AA-B2ED0C7627A1Q26862904-0B77073E-C9A8-404D-B9B7-BBB7F32350BDQ27012513-C5D42DCD-01E1-4870-92C1-ADDD2D5E8CE9Q30252082-43128BEC-33C7-4ECB-891C-D3E6F5F9CC81Q33532572-BAA13F83-FCE8-4BDA-A68C-74B21D2ED68AQ33758537-E8FBB2E1-BB37-4438-95B8-A251E50978B5Q34071540-19F3056A-8E8F-41A1-A157-EBF66245FAD8Q34459365-37FCEBE1-A6ED-4ADA-AE9A-F43C5C53670AQ35088800-0FF38D13-936D-4563-953F-4566E4B9C6AEQ35683889-364766D9-AEBC-4CB6-BA39-9164431B81AFQ35742173-53DDA050-EF39-415A-9EA9-DCBBA7501E9EQ35848092-5CAAD0DD-C324-4CFA-80BE-5767AE759FEAQ36407453-18EA7359-65D4-4A55-A03F-44EE2C0F2564Q36922091-6BCCA666-4DFC-4F3A-B69C-15DE40467F8AQ37329442-9BB574DD-09DF-4316-8093-059E055C99D2Q37372898-6CA5CFD3-E4E3-47E6-B1A1-6B3F129CB059Q37586944-340ED11D-CC91-49CA-B1B3-BF5FCFD0EFF4Q37597051-A38FCA19-B07B-4401-89D0-45761DF68E31Q37629599-F8E3136F-955F-4D22-AE6A-499F48DCA9DDQ37634744-4908C42C-044C-4EA9-AF9A-792F99E8E62DQ37717853-89336D9E-78A6-4A33-B761-1F91C99CA130Q37866341-C2F7D4D0-D12F-439B-AEB4-F9D0E266AB22Q37933440-18B7A9A1-D0A2-41D7-AC43-3AC03C2813B1Q37995864-52E6876F-1F02-49B6-9BD8-1A8EAC778B58Q38086143-421B9C39-D206-4B1B-9BEA-54E83CBC68D4Q38219092-EC1DD617-5E8B-48BD-B69E-7475FA286D9AQ38374705-33BD35F4-C6C0-430B-A00D-A4D388E2DF8AQ38656591-3D98F2BA-B27E-4E0D-981C-55DA2D486999Q38826321-16404345-DE48-4746-8B14-D1603CAEEAE3Q38921102-04E45922-84ED-4B84-8303-B6939BB78A92Q39760392-2910D04F-9824-410D-ABA2-5A7958FAACA7Q40065094-E90F0849-59E3-43A6-B0BC-F064B205B532Q40637650-DF4E237B-9F1F-4E29-B638-56C789552693Q41026374-C1F64B21-7F70-4593-96E5-1D02FEC7F6B0Q43455234-35DE89B8-F046-4093-897B-522E8BE1BE25Q44368776-7D549153-8786-4656-B06C-3EF8401AEF39Q44605525-F3CE5D14-C4C4-4A7A-B13F-669779C6D66C
P2860
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@ast
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@en
type
label
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@ast
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@en
prefLabel
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@ast
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@en
P2093
P1476
Recombinant urate oxidase for ...... nts With leukemia or lymphoma.
@en
P2093
C Hastings
G H Reaman
G Leverger
H H Mahmoud
M V Relling
S M Blaney
P304
P356
10.1200/JCO.2001.19.3.697
P407
P577
2001-02-01T00:00:00Z